Patents Assigned to Statens Serum Institut
-
Publication number: 20230298758Abstract: Methods to compute gestational age and gestational health and applications thereof are described. Generally, systems utilize analyte measurements to determine a gestational age and gestational health, which can be used as a basis to perform interventions and treat individuals.Type: ApplicationFiled: November 8, 2021Publication date: September 21, 2023Applicants: The Board of Trustees of the Leland Stanford Junior University, Statens Serum Institut, The Regents of the University of CaliforniaInventors: Liang Liang, Michael P. Snyder, Mads Melbye, Songjie Chen, Larry Rand, Laura Jelliffe-Pawlowski, Xiaotao Shen
-
Publication number: 20230225972Abstract: The present invention relates to a liposomal composition for use as a medicament. In particular, the present invention relates to a liposomal composition for use in prevention or early treatment of pathogenic infection. More specifically, the liposomal composition is used for prevention, or early treatment, of pathogenic infection in the respiratory tract, preferably by nasal or pulmonary administration.Type: ApplicationFiled: April 15, 2021Publication date: July 20, 2023Applicant: STATENS SERUM INSTITUTInventors: Frank FOLLMANN, Peter ANDERSEN, Jes DIETRICH, Dennis CHRISTENSEN
-
Publication number: 20210398682Abstract: Methods to compute gestational age and gestational health and applications thereof are described. Generally, systems utilize analyte measurements to determine a gestational age and gestational health, which can be used as a basis to perform interventions and treat individuals.Type: ApplicationFiled: March 19, 2021Publication date: December 23, 2021Applicants: The Board of Trustees of the Leland Stanford Junior University, Statens Serum InstitutInventors: Liang Liang, Jijuan Gu Urban, Mads Melbye, Michael P. Snyder
-
Patent number: 10925954Abstract: The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.Type: GrantFiled: April 18, 2018Date of Patent: February 23, 2021Assignee: Statens Serum InstitutInventors: Frank Follmann, Ida Rosenkrands, Anja Olsen, Peter Andersen
-
Patent number: 10786579Abstract: Disclosed herein is the use of Mycobacterium tuberculosis antigens for use in in vivo determination of the presence of Mtb infection in immunocompromised persons or persons co-infected with HIV and the for preparing a diagnostic reagent for skin testing (a skin test reagent) for robust assessment of the presence of Mtb infection infection in an individual wherein the individual is an immunocompromised person or a person co-infected with HIV.Type: GrantFiled: November 15, 2016Date of Patent: September 29, 2020Assignee: Statens Serum InstitutInventors: Henrik Aggerbeck, Peter Lawætz Andersen, Morten Ruhwald
-
Patent number: 10729765Abstract: The present invention discloses a delivery system for nucleic acid vaccines comprising an emulsion of tocol and esters hereof. Vaccines and new ways of administration of DNA vaccines are disclosed.Type: GrantFiled: September 17, 2015Date of Patent: August 4, 2020Assignee: Statens Serum InstitutInventor: Anders Fomsgaard
-
Patent number: 10641770Abstract: The present invention discloses in vitro and in vivo diagnostic methods with enhanced specificity and sensitivity for the detection of tuberculosis. The diagnostic reagents of the present invention can replace former mixtures/cocktails/pools of antigens comprising ESAT-6 but including ESAT6 improves the diagnosis even further.Type: GrantFiled: December 15, 2014Date of Patent: May 5, 2020Assignee: Statens Serum InstitutInventors: Claus Aagaard, Søren Tetens Hoff, Ida Rosenkrands, Else Marie Agger, Peter Lawætz Andersen
-
Patent number: 10519202Abstract: The present invention discloses a vaccine or immunogenic composition that can be administered to latently infected individuals to prevent reactivation of latent tuberculosis infection caused by species of the tuberculosis complex microorganisms (Mycobacterium tuberculosis, M. bovis, M. africanum), The invention is based on a number of M. tuberculosis derived proteins and protein fragments which are constitutively expressed in different stages of the infection. The invention is directed to the use of these polypeptides, immunologically active fragments thereof and the genes encoding them for immunological compositions such as vaccines.Type: GrantFiled: December 12, 2014Date of Patent: December 31, 2019Assignee: STATENS SERUM INSTITUTInventors: Jes Dietrich, Peter Andersen, Carina Vingsbo Lundberg, Truc Thi Kim Than Hoang
-
Publication number: 20190151479Abstract: The present invention discloses the use of Mycobacterium tuberculosis antigens for use in in vivodetermination of the presence of Mtbinfection in immunocompromised persons or persons co-infected with HIVand the for preparing a diagnostic reagent for skin testing (a skin test reagent) for robust assessment of the presence of Mtbinfection in an individual wherein the individual is an immunocompromised person or a person co-infected with HIV.Type: ApplicationFiled: November 15, 2016Publication date: May 23, 2019Applicant: Statens Serum InstitutInventors: Henrik Aggerbeck, Peter Lawætz Andersen, Morten Ruhwald
-
Patent number: 10004793Abstract: The present invention is directed to a fusion protein, antigen cocktails and immunological compositions such as vaccines against infections caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium microti, Mycobacterium canettii, Mycobacterium pinnipedii or Mycobacterium mungi. The fusion protein, antigen cocktails and immunological compositions are based on proteins secreted by the ESAT-6 secretion system 1 (ESX-1) and are among the most immunodominant M. tuberculosis (MTB) antigens.Type: GrantFiled: April 9, 2015Date of Patent: June 26, 2018Assignee: Statens Serum InstitutInventors: Claus Aagaard, Ida Rosenkrands, Truc Thi Kim Thanh Hoang, Peter Lawaetz Andersen
-
Patent number: 9764024Abstract: The invention concerns nucleotides vaccines encoding influenza proteins with few or no glycosylation sites. Since these first introductions of pandemic influenzas the viruses have drifted, accumulating mutations at antigenic sites, but also the N-glycosylation pattern has changed during the drifted years, accumulating N-linked glycosylation sequons that help mask the antigenic sites for recognition by the host immune system. These “naked” initial haemagglutinins induce a broad cross reactivity against widely drifted influenza subtypes. The origin of the DNA or RNA can be both pandemic influenza strains, which codes for proteins which have a naturally low content of glycosylation sites and/or DNA or RNA from non-pandemic influenza strains where the nucleotides have been mutated or changed so it encodes for proteins with less or no glycosylation sites. The invention also discloses DNA or RNA encoding the haemagglutinin (HA) from pandemic influenza A, e.g.Type: GrantFiled: November 27, 2009Date of Patent: September 19, 2017Assignee: Statens Serum InstitutInventors: Anders Fomsgaard, Karoline Bragstad
-
Publication number: 20170016897Abstract: The present invention discloses in vitro and in vivo diagnostic methods with enhanced specificity and sensitivity for the detection of tuberculosis. The diagnostic re agents of the present invention can replace former mixtures/cocktails/pools of antigens comprising ESAT-6 but including ESAT6 improves the diagnosis even further.Type: ApplicationFiled: December 15, 2014Publication date: January 19, 2017Applicant: STATENS SERUM INSTITUTInventors: Claus Aagaard, Søren Tetens Hoff, Ida Rosenkrands, Else Marie Agger, Peter Lawætz Andersen
-
Patent number: 9526773Abstract: The present invention is directed to fusion proteins, antigen cocktails and immunological compositions such as vaccines against infections caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium microti, Mycobacterium canettii, Mycobacterium pinnipedii or Mycobacterium mungi. The fusion proteins or antigen cocktails are based on ESX secreted or associated proteins e.g. proteins secreted by the ESAT-6 secretion system 1 (ESX-1) which are among the most immunodominant M. tuberculosis (MTB) antigens.Type: GrantFiled: October 18, 2013Date of Patent: December 27, 2016Assignee: Statens Serum InstitutInventors: Claus Aagaard, Ida Rosenkrands, Truc Thi Kim Thanh Hoang, Peter Andersen
-
Patent number: 9523131Abstract: Dermatophytes which belong to one of the three genera Epidermophyton, Trichophyton and Microsporum are the main cause of fungal infections of skin, hair and nails. Traditional diagnostic procedures consist of microscopy and culture, but due to the slow growth rate of dermatophytes typically two to four weeks are needed before a final diagnosis is obtained. The present invention is a rapid DNA extraction method extracting nucleic acids from fungi (e.g. dermatophytes and other pathogenic fungi) which can be performed from directly on hair, nail or skin specimens from humans, from naturally or experimentally infected animals or from cultured fungal colonies for the use in PCR amplification and detection assays. The present invention also includes specific primer sets for detection of any dermatophyte and for species specific detection of Trichophyton rubrum and Epidermophyton floccosum by PCR and a kit for diagnosing fungal infections.Type: GrantFiled: February 7, 2014Date of Patent: December 20, 2016Assignee: Statens Serum InstitutInventor: Anna H. Brillowska-Dabrowska
-
Patent number: 9410960Abstract: A method of diagnosing galactosemia in blood samples from neonates by determining GAL-1-P concentrations before 5-7 days of life is disclosed. The removal of interfering compounds allows a more specific and therefore more accurate determination of GAL-IP levels in newborn screening for galactosemia using mass spectrometry. This is of major importance when investigating samples from children that have not yet achieved a steady state of GAL-IP (i.e. before 5-7 day of life).Type: GrantFiled: November 28, 2013Date of Patent: August 9, 2016Assignee: Statens Serum InstitutInventor: Arieh Sierra Cohen
-
Patent number: 9279160Abstract: MRSA CC398 is a clone of S. aureus that has recently emerged in pigs and other domestic animals worldwide. As any other MRSA, the clone displays high levels of antibiotic resistance and poses a serious threat to human health because of the risk of antibiotic treatment failure in human patients. We developed a new diagnostic test for identification of MRSA CC398 using a single one-step PCR that is very easily performed within a few hours. The test is based on the principle that clonal differences within S. aureus are reflected in the sequence of a gene (sau1hsdS1) located on the chromosome of this bacterial species. Accordingly, such a gene represents an optimal target for S. aureus and MRSA identification at the clone level. The test includes detection of the gene conferring methicillin resistance (mecA), therefore allowing rapid discrimination between methicillin-susceptible and methicillin-resistant variants of the clone.Type: GrantFiled: June 17, 2010Date of Patent: March 8, 2016Assignees: Statens Serum Institut, The University of Copenhagen, St Georges Hospital Medical SchoolInventors: Marc Stegger, Luca Guardabassi, Jodi Lindsay
-
Patent number: 9140691Abstract: A diagnostic test and method is provided comprising mixing blood or another biological fluid sample with a test compound and spotting the blood on filter paper for subsequent analysis of the effect of the test compound on the blood. The biological fluid can be a cerebrospinal fluid, a peritoneal fluid, a cyst fluid, an amniotic fluid, a lavage fluid, a saliva, a cell extract or a tissue extract. The compound is chosen among an amino acid, a peptide, a protein, a carbohydrate, an oligosaccharide, a polysaccharide, a glycoprotein, a lipid, a lipoprotein, a glycosaminoglycan, a hormone, a steroid, a vitamin, a low molecular weight synthetic or natural compound which influences the blood to cause an alteration of its composition, e.g., a toxin, allergen, autoantigen, bacterial protein or polysaccharide, viral protein, fungal protein or polysaccharide, parasitic protein or polysaccharide, bacterial lipopolysaccharide or any other compound relevant to diseases.Type: GrantFiled: November 30, 2007Date of Patent: September 22, 2015Assignee: Statens Serum InstitutInventors: Gunnar Houen, David Hougaard, Kristin Skogstrand, Charlotte Svaerke Jørgensen
-
Patent number: 9074001Abstract: The present invention discloses a vaccine or immunogenic composition that can be administered to latently infected individuals to prevent reactivation of latent tuberculosis infection caused by species of the tuberculosis complex microorganisms (Mycobacterium tuberculosis, M. bovis, M. africanum). The invention is base on a number of M. tuberculosis derived proteins and protein fragments which are constitutively expressed in different stages of the infection. The invention is directed to the use of these polypeptides, immunologically active fragments thereof and the genes encoding them for immunological compositions such as vaccines.Type: GrantFiled: April 23, 2010Date of Patent: July 7, 2015Assignee: STATENS SERUM INSTITUTInventors: Jes Dietrich, Peter Andersen, Carina Vingsbo Lundberg, Truc Thi Kim Than Hoang
-
Patent number: 8889142Abstract: The present invention is related to antigen from Chlamydia trachomatis which are recognized by specific antibodies from individuals infected with Chlamydia or which can induce T cells from the same individuals to secrete gamma-interferon. The T cell reactive antigens are present in a whole-cell lysate and have apparent molecular weights of 5-12, 16-20, 25-35 and 58-74 kDa as determined by SDS-PAGE. The antigens of the invention are believed to be useful in vaccines but also as diagnostic compositions.Type: GrantFiled: October 11, 2005Date of Patent: November 18, 2014Assignee: Statens Serum InstitutInventors: Michael Theisen, Anja Olsen, Robert Leah, Frank Follmann, Klaus Jensen, Peter Andersen
-
Patent number: RE46583Abstract: Vaccination with the combination of Ag85B-TB10.4 and IC31® adjuvant generated a high amount of polyfunctional CD4+T cells expressing high levels of IFN-?, TNF-?, and IL-2. This in turn led to significant protection against infection with M. tuberculosis in the mouse aerosol challenge model of tuberculosis. Both the immunogenicity of the vaccine and its ability to protect against TB infection was highly dependent on the antigen dose. Thus, whereas the standard antigen dose of 5 ?g, as well as 15 ?g, did not induce significant protection against M. tuberculosis, reducing the dose to 0.5 ?g increased both the immunogenicity of the vaccine as well as its protective efficacy to a level comparable to that observed in BCG vaccinated mice. Thus, the IC31® adjuvant, with the specified antigen dose, can induce a strong protective Th1 response against M. tuberculosis.Type: GrantFiled: September 11, 2015Date of Patent: October 24, 2017Assignee: Statens Serum InstitutInventors: Jes Dietrich, Claus Aagaard, Peter Andersen